FRANKFURT, Oct 8 (Reuters) - Denmark's Zealand Pharma

and German partner Boehringer Ingelheim have won the

U.S. Food and Drug Administration's Breakthrough Therapy for the

review of their experimental weight-loss drug for the treatment

of a type of fatty liver disease.

The companies said in a statement that the FDA's speedier

review will be for the use of drug candidate survodutide in

non-cirrhotic metabolic dysfunction-associated steatohepatitis

(MASH).

They added that they were starting two survodutide studies

in the last of three stages of testing on humans to treat MASH

and liver scarring.